<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.2.475">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">

<meta name="author" content="Haodong Li and Andrew Mertens">

<title>Targeted Learning Heterogeneous Treatment Effect Parameters</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1.6em;
  vertical-align: middle;
}
</style>


<script src="JICI_WG_report_files/libs/clipboard/clipboard.min.js"></script>
<script src="JICI_WG_report_files/libs/quarto-html/quarto.js"></script>
<script src="JICI_WG_report_files/libs/quarto-html/popper.min.js"></script>
<script src="JICI_WG_report_files/libs/quarto-html/tippy.umd.min.js"></script>
<script src="JICI_WG_report_files/libs/quarto-html/anchor.min.js"></script>
<link href="JICI_WG_report_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="JICI_WG_report_files/libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="JICI_WG_report_files/libs/bootstrap/bootstrap.min.js"></script>
<link href="JICI_WG_report_files/libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="JICI_WG_report_files/libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">


</head>

<body class="fullcontent">

<div id="quarto-content" class="page-columns page-rows-contents page-layout-article">

<main class="content" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default">
<div class="quarto-title">
<h1 class="title">Targeted Learning Heterogeneous Treatment Effect Parameters</h1>
<p class="subtitle lead">Methods, Simulations results, and Example Analysis with LEADER Trial Data</p>
</div>



<div class="quarto-title-meta">

    <div>
    <div class="quarto-title-meta-heading">Author</div>
    <div class="quarto-title-meta-contents">
             <p>Haodong Li and Andrew Mertens </p>
          </div>
  </div>
    
  
    
  </div>
  

</header>

<section id="abstract" class="level2">
<h2 class="anchored" data-anchor-id="abstract">Abstract</h2>
</section>
<section id="introduction" class="level2">
<h2 class="anchored" data-anchor-id="introduction">Introduction</h2>
<p>Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide, accounting for over 17 million deaths each year according to the World Health Organization. Dyslipidemia is a major risk factor for CVD, and statins are among the most commonly prescribed medications for treating it. Statins have been shown to reduce the incidence of CVD events and improve patient outcomes. However, despite their benefits, statins have been associated with an increased risk of developing type 2 diabetes (T2D).</p>
<p>While the mechanisms underlying the increased risk of T2D associated with statin use remain unclear, recent evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of medications used in the treatment of T2D, may mitigate the risk of T2D associated with statin use. GLP-1RAs exert their effects through the incretin system, which plays a role in regulating glucose metabolism and insulin secretion. The incretin system is also involved in the regulation of lipid metabolism, and GLP-1RAs have been shown to improve lipid profiles in patients with T2D. However, the effect of GLP-1RA initiation on statin-associated CVD risk remains unclear.</p>
<p>In this study, we aim to investigate the treatment effect heterogeneity of statin use on CVD risk, with a focus on the effect modification of GLP-1RA initiation. We will use data from the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, a large randomized controlled trial of patients with T2D and high cardiovascular risk, to address this question. We will apply targeted maximum likelihood estimation to estimate the variable importance measure (VIM) of statin use on CVD risk. The VIM provides a measure of the importance of a variable in predicting the outcome of interest, and can be used to identify subgroups of patients who may benefit from a particular treatment.</p>
<p>We will also investigate whether GLP-1RA initiation modifies the effect of statin use on CVD risk. This is important because if GLP-1RAs can reduce the risk of CVD associated with statin use, it would have important implications for the clinical management of dyslipidemia and CVD prevention. Our findings may also help to inform personalized treatment strategies for patients with T2D and high cardiovascular risk.</p>
</section>
<section id="methods" class="level2">
<h2 class="anchored" data-anchor-id="methods">Methods</h2>
</section>
<section id="motivation" class="level2">
<h2 class="anchored" data-anchor-id="motivation">Motivation</h2>
<ul>
<li>Recent evidence showed that novel therapies such as glucagon-like peptide 1 (GLP-1) analogues can reduce the rates of major cardiovascular events in patients with type 2 diabetes.</li>
<li>The cardiovascular effect of liraglutide, GLP-1 analogue, was investigated in the LEADER trial.</li>
<li>GLP-1 users are also often on statins and other cardiovascular drugs.
<ul>
<li>Statins are a lipid lowering drug class used for primary prevention of cardiovascular diseases.</li>
<li>A retrospective cohort study found that statin use was associated with diabetes progression.</li>
</ul></li>
<li>In this project, we use novel estimating methods to further explore the heterogeneity of liraglutide treatment effect among concomitant medication (especially statin) users, with data from the randomized LEADER trial.</li>
</ul>
</section>
<section id="abstract-from-methods-paper" class="level2">
<h2 class="anchored" data-anchor-id="abstract-from-methods-paper">ABSTRACT FROM METHODS PAPER:</h2>
<p>“Heterogeneous treatment effect is an important measure for understanding how a commercial product or medical treatment affects different subgroups in a population. Beyond the overall impact reflected by the average treatment effect, the analysis of treatment effect heterogeneity further reveals details on the importance of different covariates and their relations to the outcome. A fundamental parameter on heterogeneity is the variance of treatment effect. Based on that, people defined the treatment effect variable importance parameters, which measures the heterogeneity explained by a subset of covariates of interest. In this article, we propose a new targeted maximum likelihood estimator for a treatment effect variable importance measure. This estimator is a pure plug-in estimator that consists of two steps: 1) the initial estimation of relevant components to plug in and 2) an iterative updating step to optimize the bias-variance tradeoff. The simulation results show that this TMLE estimator has competative performance in terms of lower bias and higher coverage compared to the simple substitution estimator and the estimating equation estimator.”</p>
</section>
<section id="approach" class="level2">
<h2 class="anchored" data-anchor-id="approach">Approach</h2>
<ul>
<li><p>Methods for the study of treatment effect heterogeneity is an active area of research in causal inference and statistics, and includes the estimation of conditional average treatment effects (CATE).</p></li>
<li><p>Existing hypothesis tests and estimating approaches on CATE include nearest-neighbor matching, kernel methods, series estimation, and forest-based methods.</p></li>
<li><p>One recent tranche of literature has recommended variance of treatment effect (VTE) as a global measure of treatment effect heterogeneity given a set of baseline covariates (Levy et al 2019).</p></li>
<li><p>The previous work on how to utilize these CATE estimates mainly focus on policy learning and optimal dynamic treatment rule (OTR), where people try to make personalized recommendation based on individual-level characteristics.</p></li>
<li><p>Later in 2022, Oliver Hines emphasized the importance of shifting the attention from policy learning to addressing the question of “what are the key drivers of treatment effect heterogeneity?”, and discussed on how to quantify the importance of variable subsets in determining the CATE.</p>
<ul>
<li><p>Methods have been proposed to estimate treatment effect variable importance (TE-VIMs) through the contribution of groups of baseline covariates towards the VTE.</p></li>
<li><p>These methods require estimation of a mean outcome (binary or continuous) given treatment and covariates, which may be estimated using flexible data-adaptive/ machine learning methods.</p></li>
</ul></li>
</ul>
</section>
<section id="estimation" class="level2">
<h2 class="anchored" data-anchor-id="estimation">Estimation</h2>
<p>Highly adaptive lasso (HAL).</p>
</section>
<section id="add-short-section-on-simulation-results-and-the-approach-taken-in-the-main-analysis" class="level1">
<h1>ADD SHORT SECTION ON SIMULATION RESULTS AND THE APPROACH TAKEN IN THE MAIN ANALYSIS</h1>
<ul>
<li>TMLE still performs the best asymptotically.</li>
<li>When sample size is small/moderate, EE estimates have smaller bias.</li>
<li>But the reduction in bias is negligible given the magnitude of the standard error.</li>
<li>So the coverage will still be dominated by the accuracy of standard error estimates.
<ul>
<li>This is reflected in the coverage plot panel (TMLE still got better coverage although it has slightly larger bias than EE)</li>
</ul></li>
</ul>
<section id="leader-analysis" class="level2">
<h2 class="anchored" data-anchor-id="leader-analysis">LEADER analysis</h2>
</section>
<section id="primary-outcome-diabetes-progression" class="level2">
<h2 class="anchored" data-anchor-id="primary-outcome-diabetes-progression">Primary outcome: diabetes progression</h2>
<ol type="1">
<li>Binary indicator of whether any of the following occurred within the first t=2 years of follow up.
<ol type="1">
<li>insulin initiation</li>
<li>adding glucose-lowering drugs</li>
<li>hyperglycemia</li>
<li>hypoglycemia</li>
<li>acid-base disorders</li>
</ol></li>
</ol>
</section>
<section id="primary-outcome-alternative" class="level2">
<h2 class="anchored" data-anchor-id="primary-outcome-alternative">Primary outcome: alternative</h2>
<p>Note the primary outcome drops all subjects on insulin at baseline. We will also use an alternative composite outcome using insulin intensification</p>
<table class="table">
<thead>
<tr class="header">
<th>Baseline</th>
<th>New initiation</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>No insulin treatment</td>
<td>Any insulin</td>
</tr>
<tr class="even">
<td>Long acting</td>
<td>Premix or short acting</td>
</tr>
<tr class="odd">
<td>Intermediate acting</td>
<td>Premix or short acting</td>
</tr>
</tbody>
</table>
</section>
<section id="secondary-outcomes-not-run-yet" class="level2">
<h2 class="anchored" data-anchor-id="secondary-outcomes-not-run-yet">Secondary outcomes (not run yet)</h2>
<ul>
<li>Secondary outcomes (LEADER endpoint): a time-to-event outcome composed of the first occurrence of death from cardio-vascular causes, nonfatal myocardial infarction, or nonfatal stroke.</li>
<li>Individual outcomes making up the composite outcomes</li>
</ul>
<p><strong>COMMENT:</strong> these haven’t been run yet, right? What is CV and A1C?</p>
</section>
<section id="dataset" class="level2">
<h2 class="anchored" data-anchor-id="dataset">Dataset</h2>
<p>After initial data cleaning process, the full dataset includes 9339 observations with 54 columns. For the analytic dataset using the primary outcome definition, 5170 observations who were on insulin use at the basedline are dropped from the data. In addition, 181 people who were censored/died before t (2 years) are also dropped. We impute the missing values by median and mode respectively for continuous and discrete covariates, and create missingness indicator columns. The finalized analytic dataset has 3988 rows and 63 columns.</p>
<p><strong>COMMENT:</strong> Get N’s for all outcomes</p>
<div class="cell">
<div class="cell-output cell-output-stdout">
<pre><code>355 people censored before 24 months are dropped.</code></pre>
</div>
<div class="cell-output cell-output-stdout">
<pre><code>355 people censored before 24 months are dropped.</code></pre>
</div>
<div class="cell-output cell-output-stdout">
<pre><code>355 people censored before 24 months are dropped.</code></pre>
</div>
<div class="cell-output cell-output-stdout">
<pre><code>355 people censored before 24 months are dropped.</code></pre>
</div>
</div>
</section>
<section id="descriptive-stats" class="level2">
<h2 class="anchored" data-anchor-id="descriptive-stats">Descriptive stats</h2>
<p>-tabulate outcome -both components and number of diabetes intensification outcomes</p>
<p>-tabulate number of people dropped in different analyses</p>
<p>-tabulate statins and other medication usages</p>
<div class="cell">
<div class="cell-output cell-output-stdout">
<pre><code>[1] "Diabetes intensification: 3474/8984 (38.67%)"</code></pre>
</div>
<div class="cell-output cell-output-stdout">
<pre><code>[1] "Diabetes intensification (insulin initiation definition): 661/3988 (16.57%)"</code></pre>
</div>
<div class="cell-output cell-output-stdout">
<pre><code>[1] "Cardiovascular event: 467/8984 (5.2%)"</code></pre>
</div>
<div class="cell-output cell-output-stdout">
<pre><code>[1] "HbA1c: 1/8967 (0.01%)"</code></pre>
</div>
</div>
</section>
<section id="estimation-of-variance-of-treatment-effect-parameter-1" class="level2">
<h2 class="anchored" data-anchor-id="estimation-of-variance-of-treatment-effect-parameter-1">Estimation of Variance of Treatment Effect (Parameter 1)</h2>
<div class="cell">

</div>
<p>Insignificant variance of the treatment effect on diabetes intensification:</p>
<p>Variance of the treatment effect of secondary outcomes:</p>
<ul>
<li>Cardiovascular disease:</li>
<li>HbA1c:</li>
<li>Diabetes progression (insulin initiation definition):</li>
</ul>
<p><strong>COMMENT:</strong> Why is the CV VTE 0?</p>
</section>
<section id="variable-importance-for-treatment-heterogeneity" class="level2">
<h2 class="anchored" data-anchor-id="variable-importance-for-treatment-heterogeneity">Variable importance for treatment heterogeneity</h2>
</section>
<section id="stratified-cate" class="level2">
<h2 class="anchored" data-anchor-id="stratified-cate">Stratified CATE</h2>
<div class="cell">
<div class="cell-output-display">
<p><img src="JICI_WG_report_files/figure-html/unnamed-chunk-5-1.png" class="img-fluid" width="672"></p>
</div>
<div class="cell-output-display">
<p><img src="JICI_WG_report_files/figure-html/unnamed-chunk-5-2.png" class="img-fluid" width="672"></p>
</div>
<div class="cell-output-display">
<p><img src="JICI_WG_report_files/figure-html/unnamed-chunk-5-3.png" class="img-fluid" width="672"></p>
</div>
<div class="cell-output-display">
<p><img src="JICI_WG_report_files/figure-html/unnamed-chunk-5-4.png" class="img-fluid" width="672"></p>
</div>
</div>
<p><strong>COMMENT:</strong> Format plot sizes, split/discuss by outcomes</p>
</section>
<section id="effect-modification" class="level2">
<h2 class="anchored" data-anchor-id="effect-modification">Effect modification</h2>
<div class="cell">
<div class="cell-output-display">
<p><img src="JICI_WG_report_files/figure-html/unnamed-chunk-6-1.png" class="img-fluid" width="672"></p>
</div>
</div>
</section>
<section id="variable-importance" class="level2">
<h2 class="anchored" data-anchor-id="variable-importance">Variable importance</h2>
<div class="cell">
<div class="cell-output-display">
<p><img src="JICI_WG_report_files/figure-html/unnamed-chunk-7-1.png" class="img-fluid" width="672"></p>
</div>
<div class="cell-output-display">
<p><img src="JICI_WG_report_files/figure-html/unnamed-chunk-7-2.png" class="img-fluid" width="672"></p>
</div>
<div class="cell-output-display">
<p><img src="JICI_WG_report_files/figure-html/unnamed-chunk-7-3.png" class="img-fluid" width="672"></p>
</div>
<div class="cell-output-display">
<p><img src="JICI_WG_report_files/figure-html/unnamed-chunk-7-4.png" class="img-fluid" width="672"></p>
</div>
</div>
</section>
<section id="questions" class="level2">
<h2 class="anchored" data-anchor-id="questions">Questions:</h2>
<ol type="1">
<li>What are other options (outcome definition or subgroup definition) we can consider for LEADER trial data?</li>
<li>Are there other data we can use to apply this TMLE heterogeneious effect estimation method to, where we might found more significant treatment heterogeneity?</li>
</ol>
</section>
<section id="next-steps" class="level2">
<h2 class="anchored" data-anchor-id="next-steps">Next steps:</h2>
<ol type="1">
<li>Investigate why TMLE point estimates of the VIM parameter in LEADER analysis are overall larger than the EE estimates.</li>
<li>Compare the causal forest method for heterogeneity estimation with our TMLE approach.</li>
<li>Test more simple robust estimating method, for example: the plug-in HAL method. One option is to use undersmoothed HAL or the poisson HAL method (direct estimate the conditional density via conditional hazard) proposed by Helene and Mark.</li>
<li>Extend methods to time-to-event outcomes</li>
<li>Others?</li>
</ol>
</section>
<section id="supplementary-materials" class="level2">
<h2 class="anchored" data-anchor-id="supplementary-materials">Supplementary materials</h2>
<p>https://www.overleaf.com/project/63e061cf03b08e985e4d9d1f</p>
</section>
<section id="supplementary-table-1-descriptive-statistics" class="level2">
<h2 class="anchored" data-anchor-id="supplementary-table-1-descriptive-statistics">Supplementary table 1: Descriptive statistics</h2>
<div class="cell">
<div class="cell-output cell-output-stdout">
<pre><code>355 people censored before 24 months are dropped.</code></pre>
</div>
<div class="cell-output cell-output-stdout">
<pre><code>
================================================================
Statistic                    N    Mean   St. Dev.  Min     Max  
----------------------------------------------------------------
A                          3,988  0.489   0.500     0       1   
AGE                        3,987 64.388   7.120     50     88   
DIABDUR                    3,982 15.309   7.989   0.100  61.000 
INCPASSN                   3,988  4.995   0.067     4       5   
BMIBL                      3,985 32.869   6.289   18.000 81.000 
PULSEBL                    3,988 72.746   11.392    35     172  
SYSBPBL                    3,988 136.121  18.287  72.500 227.000
DIABPBL                    3,988 76.078   10.332  38.500 127.000
HBA1CBL                    3,988  8.875   1.557   5.100  18.500 
HDL1BL                     3,922  1.168   0.319   0.080   3.320 
LDL1BL                     3,922  2.291   0.919   0.200   8.230 
CHOL1BL                    3,922  4.341   1.125   1.810  12.580 
RC                         3,922  0.883   0.539   -0.910 11.030 
RCoverHDL                  3,922  0.867   0.765   -0.820 14.707 
TRIG1BL                    3,922  2.027   1.516   0.360  36.090 
CREATBL                    3,988 90.497   41.846    20     726  
EGFMDRBC                   3,988 77.936   27.964  6.800  418.500
HBA1CGRN                   3,988  1.551   0.497     1       2   
DDURGRN                    3,982  1.668   0.471     1       2   
Y                          3,988  0.341   0.474     0       1   
SEX.F                      3,988  0.384   0.486     0       1   
SEX.M                      3,988  0.616   0.486     0       1   
RACE.ASIAN                 3,988  0.099   0.298     0       1   
RACE.BLACK                 3,988  0.097   0.296     0       1   
RACE.OTHER                 3,988  0.039   0.194     0       1   
RACE.WHITE                 3,988  0.766   0.424     0       1   
COUNTRY.Africa             3,988  0.035   0.183     0       1   
COUNTRY.America            3,988  0.467   0.499     0       1   
COUNTRY.Asia               3,988  0.162   0.369     0       1   
COUNTRY.Europe             3,988  0.305   0.461     0       1   
COUNTRY.Pacific            3,988  0.031   0.174     0       1   
SMOKER.CURRENT.SMOKER      3,988  0.115   0.319     0       1   
SMOKER.NEVER.SMOKED        3,988  0.418   0.493     0       1   
SMOKER.PREVIOUS.SMOKER     3,988  0.466   0.499     0       1   
NYHACLAS.NYHA.CLAS.NA      3,988  0.831   0.375     0       1   
NYHACLAS.NYHA.CLASS.I      3,988  0.035   0.185     0       1   
NYHACLAS.NYHA.CLASS.II     3,988  0.113   0.316     0       1   
NYHACLAS.NYHA.CLASS.III    3,988  0.021   0.144     0       1   
ANTDBFL...1.OADs           3,988  0.000   0.000     0       0   
ANTDBFL.1.OAD              3,988  0.000   0.000     0       0   
ANTDBFL.Insulin.OAD        3,988  0.172   0.377     0       1   
ANTDBFL.Insulin.OAD.s.     3,988  0.828   0.377     0       1   
ANTDBFL.None               3,988  0.000   0.000     0       0   
AHYPERFL.FALSE             3,988  0.908   0.289     0       1   
AHYPERFL.TRUE              3,988  0.092   0.289     0       1   
RETINSEV.no.retinopathy    3,988  0.017   0.130     0       1   
RETINSEV.non.proliferative 3,988  0.198   0.399     0       1   
RETINSEV.proliferative     3,988  0.076   0.265     0       1   
RETINSEV.retinsev.NA       3,988  0.709   0.454     0       1   
GERDBLFL.FALSE             3,988  0.553   0.497     0       1   
GERDBLFL.TRUE              3,988  0.447   0.497     0       1   
PPIFL.FALSE                3,988  0.769   0.422     0       1   
PPIFL.TRUE                 3,988  0.231   0.422     0       1   
H2BLFL.FALSE               3,988  0.962   0.192     0       1   
H2BLFL.TRUE                3,988  0.038   0.192     0       1   
MIFL.FALSE                 3,988  0.690   0.463     0       1   
MIFL.TRUE                  3,988  0.310   0.463     0       1   
STROKEFL.FALSE             3,988  0.828   0.377     0       1   
STROKEFL.TRUE              3,988  0.172   0.377     0       1   
REVASFL.FALSE              3,988  0.589   0.492     0       1   
REVASFL.TRUE               3,988  0.411   0.492     0       1   
STENFL.FALSE               3,988  0.739   0.439     0       1   
STENFL.TRUE                3,988  0.261   0.439     0       1   
CHDFL.FALSE                3,988  0.911   0.285     0       1   
CHDFL.TRUE                 3,988  0.089   0.285     0       1   
IHDFL.FALSE                3,988  0.742   0.437     0       1   
IHDFL.TRUE                 3,988  0.258   0.437     0       1   
CHFFL.FALSE                3,988  0.866   0.341     0       1   
CHFFL.TRUE                 3,988  0.134   0.341     0       1   
KIDFL.FALSE                3,988  0.709   0.454     0       1   
KIDFL.TRUE                 3,988  0.291   0.454     0       1   
MICFL.FALSE                3,988  0.715   0.452     0       1   
MICFL.TRUE                 3,988  0.285   0.452     0       1   
HYPFL.FALSE                3,988  0.763   0.425     0       1   
HYPFL.TRUE                 3,988  0.237   0.425     0       1   
LVSDFL.FALSE               3,988  0.771   0.420     0       1   
LVSDFL.TRUE                3,988  0.229   0.420     0       1   
PADFL.FALSE                3,988  0.864   0.343     0       1   
PADFL.TRUE                 3,988  0.136   0.343     0       1   
CVRISK.High                3,988  0.830   0.376     0       1   
CVRISK.Medium              3,988  0.170   0.376     0       1   
statin_use.FALSE           3,988  0.246   0.431     0       1   
statin_use.TRUE            3,988  0.754   0.431     0       1   
antihypertensives.FALSE    3,988  0.173   0.378     0       1   
antihypertensives.TRUE     3,988  0.827   0.378     0       1   
betab.FALSE                3,988  0.428   0.495     0       1   
betab.TRUE                 3,988  0.572   0.495     0       1   
minera.FALSE               3,988  0.938   0.242     0       1   
minera.TRUE                3,988  0.062   0.242     0       1   
adp.FALSE                  3,988  0.263   0.440     0       1   
adp.TRUE                   3,988  0.737   0.440     0       1   
vkantag.FALSE              3,988  0.938   0.242     0       1   
vkantag.TRUE               3,988  0.062   0.242     0       1   
caantag.FALSE              3,988  0.659   0.474     0       1   
caantag.TRUE               3,988  0.341   0.474     0       1   
thiazide.FALSE             3,988  0.812   0.390     0       1   
thiazide.TRUE              3,988  0.188   0.390     0       1   
loopdiur.FALSE             3,988  0.789   0.408     0       1   
loopdiur.TRUE              3,988  0.211   0.408     0       1   
----------------------------------------------------------------</code></pre>
</div>
</div>
<section id="variance-of-the-treatment-effect-ee-estimator-alternative" class="level4">
<h4 class="anchored" data-anchor-id="variance-of-the-treatment-effect-ee-estimator-alternative">Variance of the treatment effect (EE estimator alternative):</h4>
<p>Insignificant variance of the treatment effect on diabetes intensification:</p>
<p>Variance of the treatment effect of secondary outcomes:</p>
<ul>
<li>Cardiovascular disease:</li>
<li>HbA1c:</li>
<li>Diabetes progression (insulin initiation definition):</li>
</ul>
</section>
</section>
</section>

</main>
<!-- /main column -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    target: function(trigger) {
      return trigger.previousElementSibling;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->



</body></html>